IntelliPharmaCeutics (IPCI) Pathway for Rexista NDA 'Significantly Shortened', Brean Capital Says
Tweet Send to a Friend
Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and $8 price target on IntelliPharmaCeutics International (NASDAQ: IPCI) noting the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
